FrancophonIA/ELRC3.0 huggingface dataset:
English: Visually inspect the diluted solution before administration.
Danish: Inspicér den fortyndede infusionsvæske visuelt inden administration.
English: STELARA 90 mg solution for injection 1 mL solution in a type I glass 2 mL vial closed with a coated butyl rubber stopper.
Danish: STELARA 90 mg injektionsvæske, opløsning 1 ml opløsning i type 1-hætteglas med 2 ml lukket med en overtrukken butylgummiprop.
English: If you have used or been given too much Stelara, talk to a doctor or pharmacist straight away.
Danish: Brug af anden medicin eller vacciner sammen med Stelara Fortæl altid lægen eller på apoteket:
English: PGA b of cleared or minimal N
Danish: b clear eller minimal
English: Combined symptomatic remission and mucosal healing is defined as a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1. p<0.001 p<0.05
Danish: Kombineret symptomatisk remission og slimhindeheling defineres som en subscore for afføringshyppighed på 0 eller 1, en subscore for rektal blødning på 0 og en subscore for endoskopi på 0 eller 1. p < 0,001 p < 0,05
English: Dose linearity
Danish: Linearitet
English: The clinical development program consisted of one intravenous induction study (referred to as UNIFI-I) with treatment of up to 16 weeks followed by a
Danish: Det kliniske udviklingsprogram bestod af ét studie med intravenøs induktion (kaldet UNIFI-I) med behandling i op til 16 uger efterfulgt af et 44-ugers randomiseret tilbagetrækningsstudie med subkutan vedligeholdelse (kaldet UNIFI-M), hvilket sammenlagt udgjorde mindst 52 ugers behandling.
English: • Peeling of the skin (skin exfoliation)
Danish: • Hudafskalning (hudeksfoliation)
English: In patients who failed biological therapy In patients who failed both a TNF and vedolizumab Clinical Response
Danish: hos patienter, som ikke responderede på biologisk behandling hos patienter, som ikke responderede hverken på en TNF eller vedolizumab Slimhindeheling
English: Patients were randomised to receive treatment with ustekinumab 45 mg, 90 mg, or placebo subcutaneously at Weeks 0 and 4 followed by every 12 weeks (q12w) dosing.
Danish: Patienterne blev randomiseret til behandling med ustekinumab 45 mg, 90 mg eller placebo indgivet subkutant i uge 0 og 4 og derefter hver 12. uge.
English: What Stelara looks like and contents of the pack Stelara is a clear to slightly opalescent (having a pearl-like shine), colourless to light yellow solution for injection.
Danish: Stelara er en klar til let opaliserende (med perlemorsskær), farveløs til lys gul injektionsvæske.
English: Patients randomised to receive placebo at Weeks 0 and 4 crossed over to receive ustekinumab (either 45 mg or 90 mg) at Weeks 12 and 16 followed by dosing every 12 weeks.
Danish: De patienter, der var randomiseret til at få placebo i uge 0 og 4, skiftede til at få ustekinumab (enten 45 mg eller 90 mg) i uge 12 og 16 efterfulgt af administration hver 12. uge.
English: If you forget or miss the appointment for receiving the dose, contact your doctor to reschedule your appointment.
Danish: Hvis du har glemt at få Stelara Kontakt lægen, hvis du glemmer eller ikke når aftalen hos lægen, hvor du skal have din dosis.
English: Stelara is intended for use under the guidance and supervision of a doctor experienced in treating conditions for which STELARA is intended.
Danish: Stelara er beregnet til brug under vejledning og tilsyn af en læge med erfaring i at behandle de sygdomme, som Stelara er beregnet til.
English: In the controlled and non-controlled periods of psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis clinical studies, representing 11,561 patient-years of exposure in 6,709 patients, the median follow-up was 1.0 years; 1.1 years for psoriatic disease studies, 0.6 year for Crohn's disease studies and 1.0 years for ulcerative colitis studies.
Danish: I de kontrollerede og ikke-kontrollerede perioder i kliniske studier af psoriasis, psoriasisartrit, Crohns sygdom og colitis ulcerosa, der udgjorde 11.561 patientårs eksponering hos 6.709 patienter, var den mediane opfølgningsperiode 1,0 år - 1,1 år i psoriasissygdomsstudier, 0,6 år i studier med Crohns sygdom og 1,0 år i studier med colitis ulcerosa.
English: • the solution in the pre-filled syringe is not discoloured or cloudy and does not contain any foreign particles
Danish: • at opløsningen i den fyldte injektionssprøjte ikke er misfarvet eller uklar, og at den ikke indeholder fremmede partikler
English: STELARA 45 mg solution for injection STELARA 90 mg solution for injection STELARA 45 mg solution for injection in pre-filled syringe STELARA 90 mg solution for injection in pre-filled syringe
Danish: STELARA 45 mg injektionsvæske, opløsning STELARA 90 mg injektionsvæske, opløsning STELARA 45 mg injektionsvæske, opløsning i fyldt injektionssprøjte.
English: Number of 130 mg STELARA Vials
Danish: Antal hætteglas med 130 mg STELARA
English: Stelara.
Danish: ustekinumab.
English: Ask your doctor if you are not sure.
Danish: Spørg lægen eller på apoteket, hvis der er noget, du er i tvivl om.
English: • The other ingredients are L-histidine, L-histidine monohydrochloride monohydrate, polysorbate
Danish: • Øvrige indholdsstoffer: L-histidin, L-histidin-monohydrochlorid-monohydrat, polysorbat 80,
English: It is supplied as a carton pack containing 1 single-dose, glass 30 mL vial.
Danish: Det udleveres i en karton, der indeholder 1 dosis i et 30 ml-hætteglas af glas.
English: STELARA 45 mg solution for injection 2 years
Danish: STELARA 45 mg injektionsvæske, opløsning 2 år
English: Each vial contains 130 mg of ustekinumab in 26 mL.
Danish: Hvert hætteglas indeholder 130 mg ustekinumab i 26 ml.
English: Solution for injection in pre-filled syringe 45 mg/0.5 mL
Danish: Injektionsvæske, opløsning 45 mg/0,5 ml
English: STELARA is intended for use under the guidance and supervision of physicians experienced in the diagnosis and treatment of conditions for which STELARA is indicated.
Danish: STELARA er beregnet til brug under vejledning og supervision af læger med erfaring i diagnosticering og behandling af sygdomme, som STELARA er indiceret til.
English: In the controlled and non-controlled periods of psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis clinical studies, representing 11,581 patient-years of exposure in 6,709 patients, the median follow up was 1.0 years; 1.1 years for psoriatic disease studies, 0.6 year for Crohn's disease studies and 1.0 years for ulcerative colitis studies.
Danish: I de kontrollerede og ikke-kontrollerede perioder i de kliniske studier af psoriasis, psoriasisartrit, Crohns sygdom og colitis ulcerosa, der repræsenterede eksponering i 11.581 patientår hos 6.709 patienter, var den mediane opfølgningsperiode 1,0 år - 1,1 år i psoriasissygdomsstudier, 0,6 år i studier med Crohns sygdom og 1,0 år i studier med colitis ulcerosa.
English: The safety and efficacy of ustekinumab was assessed in three randomized, double-blind, placebo-controlled, multicenter studies in adult patients with moderately to severely active Crohn's disease (Crohn's Disease Activity Index [CDAI] score of ≥ 220 and ≤ 450).
Danish: Ustekinumabs sikkerhed og virkning blev vurderet i tre randomiserede, dobbeltblinde, placebokontrollerede, multicenterstudier hos voksne patienter med moderat til svær aktiv Crohns sygdom (Crohns Disease Activity Index [CDAI] score ≥ 220 og ≤ 450).
English: Solution for injection in pre-filled syringe 90 mg/1 mL
Danish: Injektionsvæske, opløsning 90 mg/1 ml
English: VIAL LABEL TEXT (90 mg)
Danish: HÆTTEGLASSETS ETIKET (90 mg)
English: Tell your doctor or get emergency medical help straight away if you notice any of the following signs.
Danish: Kontakt straks lægen eller skadestue, hvis du bemærker nogle af følgende tegn.
English: Justification for not including in Braille accepted.
Danish: Fritaget fra krav om brailleskrift.
English: Psoriasis Study 1
Danish: Psoriasisstudie 1 Antal randomiserede patienter
English: STELARA 90 mg injection ustekinumab
Danish: STELARA 90 mg injektionsvæske, opløsning ustekinumab
English: Table 12: Summary of Key Efficacy Measures in UNIFI-M (week 44; 52 weeks from initiation of the induction dose)
Danish: Tabel 12: Oversigt over de væsentligste effektresultater i UNIFI-M (uge 44, 52 uger fra initiering af induktionsdosen)
English: • Do not shake the Stelara vials.
Danish: • Ryst ikke hætteglasset med Stelara.
English: Excipients: Sucrose, L-histidine, L-histidine monohydrochloride monohydrate, polysorbate 80, water for injections.
Danish: Hjælpestoffer: Saccharose, L-histidin, L-histidin-monohydrochlorid-monohydrat, polysorbat 80, vand til injektionsvæsker.
English: STELARA 90 mg solution for injection 2 years
Danish: STELARA 90 mg injektionsvæske, opløsning 2 år
English: In both UNITI-1 and UNITI-2, a significantly greater proportion of patients were in clinical response and remission in the ustekinumab treated group compared to placebo (Table 3).
Danish: I både UNITI-1 og UNITI-2 opnåede en signifikant større andel af de patienter, som blev behandlet med ustekinumab, et klinisk respons og var i remission sammenlignet med dem, som fik placebo
English: The rate of infection was 0.91 per patient-year of follow-up in ustekinumab-treated patients, and the rate of serious infections was 0.02 per patient-year of follow-up in ustekinumab-treated patients (199 serious infections in 11,581 patient-years of follow-up) and serious infections reported included pneumonia, anal abscess, cellulitis, diverticulitis, gastroenteritis and viral infections.
Danish: Forekomsten af infektioner var 0,91 pr. patientår i opfølgningsperioden for patienter, der blev behandlet med ustekinumab, og forekomsten af alvorlige infektioner var 0,02 pr. patientår i opfølgningsperioden for patienter, der blev behandlet med ustekinumab (199 alvorlige infektioner i 11.581 patientår i opfølgningsperioden).
English: Clinical Remission*
Danish: Symptomatisk remission
English: What Stelara is and what it is used for What you need to know before you use Stelara How Stelara will be given Possible side effects
Danish: Det skal du vide, før du begynder at bruge Stelara Sådan skal du bruge Stelara Bivirkninger
English: EDTA disodium salt dihydrate L-histidine
Danish: Dinatriumethylendiamintetraacetat-dihydrat L-histidin
English: STELARA is supplied as a sterile, single-use vial or singleuse pre-filled syringe.
Danish: STELARA fås i et sterilt hætteglas til engangsbrug eller i en fyldt injektionssprøjte til engangsbrug.
English: In UNIFI-I a significantly greater proportion of patients were in clinical remission in the ustekinumab treated group compared to placebo at week 8 (Table 5).
Danish: I UNIFI-I opnåede en signifikant større andel af de patienter, som blev behandlet med ustekinumab, klinisk remission i uge 8 sammenlignet med dem, som fik placebo (tabel 5).
English: • The doctor will work out the recommended intravenous infusion dose for you based on your body weight.
Danish: Voksne på 18 år og derover • Lægen vil fastlægge den anbefalede intravenøse dosis til dig ud fra din kropsvægt.
English: Check the number of vials and prepare the materials:
Danish: Kontrollér antallet af hætteglas, og forbered injektionen:
English: STELARA 45 mg injection ustekinumab
Danish: STELARA 45 mg injektionsvæske, opløsning ustekinumab
English: Any unused product remaining in the vial and the syringe should be thrown away.
Danish: Eventuelt ikke anvendt medicin, der er tilbage i hætteglasset og sprøjten, skal bortskaffes.
English: It is supplied as a carton pack containing 1 single-dose, glass 2 mL vial.
Danish: Den udleveres i en karton, der indeholder 1 dosis i et 2 ml-hætteglas af glas.
English: Patients who were not in clinical response to ustekinumab induction at week 8 of the UNFI-I study but were in response at week 16 (157 patients) entered into the non-randomized portion of UNIFI-M and continued to receive maintenance dosing every 8 weeks; among these patients, a majority (62%) maintained response and 30% achieved remission at week 44.
Danish: Patienter, som ikke havde klinisk respons på induktionsbehandling med ustekinumab i uge 8 i UNIFII-studiet, men som havde respons i uge 16 (157 patienter), indgik i den ikke-randomiserede del af UNIFI-M og fortsatte med at få vedligeholdelsesdosering hver 8. uge.
English: Number of patients ≤ 100 kg PASI 75 response N (%) 12 (4%) 218 (73%) 225 (78%) 217 (76%) 226 (81%) Number of patients > 100 kg 120 PASI 75 response N (%) 3 (3%) 55 (49%) 86 (71%) 59 (54%) 88 (74%)
Danish: Antal patienter > 100 kg 120 112 PASI 75 respons N (%) 3 (3%) 55 (49%) 86 (71%)
English: In UNIFI-I a significantly greater proportion of patients were in clinical remission in the ustekinumab treated group compared to placebo at week 8 (Table 11).
Danish: I UNIFI-I opnåede en signifikant større andel af de patienter, som blev behandlet med ustekinumab, klinisk remission i uge 8 sammenlignet med dem, som fik placebo (tabel 11.
English: In both studies, patients were randomised to receive a single intravenous administration of either the recommended tiered dose of approximately 6 mg/kg (see Table 1, section 4.2), a fixed dose of 130 mg ustekinumab, or placebo at week 0.
Danish: I begge studier blev patienterne randomiseret til at få en enkelt intravenøs administration af enten den anbefalede individuelle dosis på ca. 6 mg/kg (se tabel 1, pkt.
English: Combined symptomatic remission and mucosal healing is defined as a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1. p<0.001
Danish: Kombineret symptomatisk remission og slimhindeheling defineres som en subscore for afføringshyppighed på 0 eller 1, en subscore for rektal blødning på 0 og en subscore for endoskopi på 0 eller 1. p < 0,001
English: PRE-FILLED SYRINGE LABEL TEXT (45 mg)
Danish: DEN FYLDTE INJEKTIONSSPRØJTES ETIKET (45 mg)
English: For the posology of the intravenous dosing regimen, see section 4.2 of the STELARA 130 mg Concentrate for solution for infusion SmPC.
Danish: 4.2 i produktresuméet for STELARA 130 mg koncentrat til infusionsvæske for oplysninger om dosering af det intravenøse regime.
English: Psoriasis Study 2
Danish: Psoriasisstudie 2 Antal randomiserede patienter
English: In Psoriasis Study 1, improvements in nail psoriasis (Nail Psoriasis Severity Index), in the physical and mental component summary scores of the SF-36 and in the Itch Visual Analogue Scale (VAS) were also significant in each ustekinumab treatment group compared with placebo.
Danish: Det samme gjaldt for de opsummerende scorer for komponenterne for mental og fysisk livskvalitet i SF-36 og Itch VAS (visuel analog skala for kløe) for hver behandlingsgruppe med ustekinumab sammenlignet med placebo.
English: • The other ingredients are EDTA disodium salt dihydrate, L-histidine, L-histidine monohydrochloride monohydrate, L-methionine, polysorbate 80, sucrose and water for injection.
Danish: • Øvrige indholdsstoffer: Dinatriumethylendiamintetraacetat-dihydrat, L-histidin, L-histidin monohydrochlorid-monohydrat, L-methionin, polysorbat 80, saccharose og vand til injektionsvæske.
English: STELARA 90 mg solution for injection in pre-filled syringe Each pre-filled syringe contains 90 mg ustekinumab in 1 mL.
Danish: STELARA 90 mg injektionsvæske, opløsning i fyldt injektionssprøjte Hvert hætteglas indeholder 90 mg ustekinumab i 1 ml.
English: • Do not shake Stelara vials.
Danish: • Ryst ikke hætteglassene med Stelara.
English: Excipients: EDTA disodium salt dihydrate, L-histidine, L-histidine monohydrochloride monohydrate, L-methionine, polysorbate 80, sucrose, water for injection.
Danish: Hjælpestoffer: Dinatriumethylendiamintetraacetat-dihydrat, L-histidin, L-histidin-monohydrochloridmonohydrat, L-methionin, polysorbat 80, saccharose, vand til injektionsvæske.
English: PRE-FILLED SYRINGE LABEL TEXT (90 mg)
Danish: DEN FYLDTE INJEKTIONSSPRØJTES ETIKET (90 mg)
English: The solution in the STELARA vial or pre-filled syringe should not be shaken.
Danish: Injektionsvæsken i hætteglasset eller den fyldte injektionssprøjte med STELARA må ikke rystes.
English: STELARA 45 mg solution for injection EU/1/08/494/001
Danish: STELARA 45 mg injektionsvæske, opløsning EU/1/08/494/001
English: STELARA 90 mg solution for injection EU/1/08/494/002
Danish: STELARA 90 mg injektionsvæske, opløsning EU/1/08/494/002
English: STELARA 45 mg solution for injection in pre-filled syringe Each pre-filled syringe contains 45 mg ustekinumab in 0.5 mL.
Danish: STELARA 45 mg injektionsvæske, opløsning i fyldt injektionssprøjte Hvert hætteglas indeholder 45 mg ustekinumab i 0,5 ml.
English: Before you use Stelara tell your doctor:
Danish: Kontakt lægen, før du bruger Stelara:
English: • Hold the pre-filled syringe by the body of the syringe with the covered needle pointing upward
Danish: • Hold om kappen på den fyldte injektionssprøjte med den beskyttede nål opad.
English: STELARA 90 mg solution for injection in pre-filled syringe 3 years
Danish: STELARA 90 mg injektionsvæske, opløsning i fyldt injektionssprøjte 3 år
English: Patients who were not in clinical response to ustekinumab induction at week 8 of the UNITI-1 and UNITI-2 induction studies (476 patients) entered into the non-randomized portion of the maintenance study (IM-UNITI) and received a 90 mg subcutaneous injection of ustekinumab at that time.
Danish: De patienter i induktionsstudierne UNITI-1 og UNITI-2 (476 patienter), som ikke havde klinisk respons på induktionsbehandling med ustekinumab i uge 8, overgik til den ikke-randomiserede del af vedligeholdelsesstudiet (IM-UNITI) og fik på det tidspunkt en subkutan injektion med ustekinumab på 90 mg. Otte uger senere havde 50,5% af patienterne opnået kliniske respons og fortsatte med at få vedligeholdelsesdosering hver 8. uge.
English: STELARA 45 mg solution for injection in pre-filled syringe 3 years
Danish: STELARA 45 mg injektionsvæske, opløsning i fyldt injektionssprøjte 3 år
English: • Keep the vial in the outer carton in order to protect from light.
Danish: • Opbevar hætteglasset i den ydre karton for at beskytte det mod lys.
English: • the solution in the vial is clear to slightly opalescent (having a pearl-like shine) and colourless to light yellow
Danish: • at opløsningen i hætteglasset er klar til svagt opaliserende (har et perlemorsagtigt skær), og at den er farveløs til svagt gul
English: It is supplied as a carton pack containing 1 single-dose, glass 1 mL pre-filled syringe.
Danish: Den udleveres i en karton, der indeholder 1 dosis i en 1 ml fyldt injektionssprøjte af glas.
English: Number of patients ≤ 100 kg PASI 75 response N (%) 6 (4%) 124 (74%) 107 (65%) 130 (79%) 124 (81%) Number of patients > 100 kg PASI 75 response N (%) 2 (2%) 47 (54%) 63 (68%) 48 (56%) 67 (74%)
Danish: Antal patienter > 100 kg 89 PASI 75 respons N (%) 2 (2%) 47 (54%) 63 (68%)
English: Patients were treated with the recommended dose of ustekinumab (see section 4.2; n = 44) by subcutaneous injection at weeks 0 and 4 followed by every 12 week (q12w) dosing.
Danish: 4.2; n = 44) som subkutan injektion i uge 0 og 4 efterfulgt af dosering hver 12. uge.
English: PASI 75 response N (%)
Danish: PASI 75 respons N (%) 6 (4%)
English: - If you have any further questions, ask your doctor or pharmacist.
Danish: Er du i tvivl, så spørg din læge.
English: In patients who failed conventional therapy, but not a biologic
Danish: Slimhindeheling hos patienter uden respons på konventionel behandling, men kan have responderet på et biologisk middel hos patienter, som ikke responderede på biologisk behandling
English: • Keep the pre-filled syringe in the outer carton in order to protect from light.
Danish: • Opbevar den fyldte injektionssprøjte i den ydre karton for at beskytte det mod lys.
English: • the solution in the pre-filled syringe is clear to slightly opalescent (having a pearl-like shine) and colourless to light yellow
Danish: • at opløsningen i den fyldte injektionssprøjte er klar til svagt opaliserende (har et perlemorsagtigt skær), og at den er farveløs til svagt gul.
English: • burning when passing water
Danish: • svien ved vandladning
English: Instructions for dilution:
Danish: Fortyndingsinstruktioner:
English: Each vial contains 45 mg of ustekinumab in 0.5 mL.
Danish: Hvert hætteglas indeholder 45 mg ustekinumab i 0,5 ml.
English: STELARA 130 mg concentrate for solution for infusion ustekinumab
Danish: STELARA 130 mg koncentrat til infusionsvæske, opløsning Ustekinumab
English: Keep the vial or pre-filled syringe in the outer carton in order to protect from light.
Danish: Opbevar hætteglasset eller den fyldte injektionssprøjte i den ydre karton for at beskytte mod lys.
English: Each vial contains 90 mg of ustekinumab in 1 mL.
Danish: Hvert hætteglas indeholder 90 mg ustekinumab i 1 ml.
English: Significantly greater proportions of patients were in clinical remission in both ustekinumab treated groups compared to the placebo group at week 44 (see Table 6).
Danish: En signifikant højere andel af patienterne i begge ustekinumab-grupper havde klinisk remission sammenlignet med placebo-gruppen i uge 44 (se tabel 6).
English: Patients were randomised to receive a single intravenous administration of either the recommended tiered dose of approximately 6 mg/kg (see Table 1, section 4.2), a fixed dose of 130 mg ustekinumab, or placebo at week 0.
Danish: Patienterne blev randomiseret til at få en enkelt intravenøs dosis af enten af den anbefalede individuelle dosis på ca. 6 mg/kg (se tabel 1, pkt.
English: STELARA 90 mg solution for injection in pre-filled syringe EU/1/08/494/004
Danish: STELARA 90 mg injektionsvæske, opløsning i fyldt injektionssprøjte EU/1/08/494/004
English: In both studies, patients were randomised to receive a single intravenous administration of either the recommended tiered dose of approximately 6 mg/kg (see section 4.2 of the STELARA 130 mg Concentrate for solution for infusion SmPC), a fixed dose of 130 mg ustekinumab, or placebo at week 0.
Danish: 4.2 i produktresuméet for STELARA 130 mg koncentrat til infusionsvæske, opløsning), en fast dosis på 130 mg ustekinumab eller placebo i uge 0.
English: For the posology of the subsequent subcutaneous dosing regimen, see section 4.2 of the STELARA solution for injection (vial) and solution for injection in pre-filled syringe SmPC.
Danish: 4.2 i produktresuméet for STELARA injektionsvæske, opløsning (hætteglas) og injektionsvæske, opløsning i fyldt injektionssprøjte for oplysninger om dosering af det efterfølgende subkutane regime.
English: STELARA 45 mg solution for injection Each vial contains 45 mg ustekinumab in 0.5 mL.
Danish: STELARA 45 mg injektionsvæske, opløsning Hvert hætteglas indeholder 45 mg ustekinumab i 0,5 ml.
English: • Slow down the damage to your joints.
Danish: • for at forhale ledskader.
English: STELARA 45 mg solution for injection in pre-filled syringe EU/1/08/494/003
Danish: STELARA 45 mg injektionsvæske, opløsning i fyldt injektionssprøjte EU/1/08/494/003
English: Significantly higher proportions of patients maintained clinical remission and response in the ustekinumab treated groups compared to the placebo group at week 44 (see Table 10).
Danish: En signifikant højere andel af patienterne i ustekinumab-gruppen havde vedvarende klinisk remission og respons sammenlignet med placebo-gruppen i uge 44 (se tabel 10).
English: Each pre-filled syringe contains 90 mg of ustekinumab in 1 mL.
Danish: Hver fyldt injektionssprøjte indeholder 90 mg ustekinumab i 1 ml.
English: Do not squeeze it tightly
Danish: Du skal ikke presse hårdt.
English: • If you have ever had any type of cancer - this is because immunosuppressants like Stelara weaken part of the immune system.
Danish: Immunsuppressiva som Stelara svækker dele af immunsystemet.
English: Each pre-filled syringe contains 90 mg ustekinumab in 1 mL of solution for injection.
Danish: Hver fyldt injektionssprøjte indeholder 90 mg ustekinumab i 1 ml injektionsvæske.
English: STELARA 90 mg solution for injection Each vial contains 90 mg ustekinumab in 1 mL.
Danish: STELARA 90 mg injektionsvæske, opløsning Hvert hætteglas indeholder 90 mg ustekinumab i 1 ml.
English: Each pre-filled syringe contains 45 mg of ustekinumab in 0.5 mL.
Danish: Hver fyldt injektionssprøjte indeholder 45 mg ustekinumab i 0,5 ml.